Mountain View, CA, United States of America

Ivan Lobal

This inventor holds 1 USPTO granted patent. Top assignees: Kirin Beer Kabushiki Kaisha, Nuvelo, Inc.. Active years: 2008.


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Ivan Lobal

Introduction

Ivan Lobal is a notable inventor based in Mountain View, CA (US). He has made significant contributions to the field of biotechnology, particularly in the area of hematopoietic stem cell research. His work has implications for medical advancements and therapeutic applications.

Latest Patents

Ivan Lobal holds a patent for a polypeptide that supports the proliferation or survival of hematopoietic stem cells and hematopoietic progenitor cells. The patent describes a gene encoding a polypeptide that is isolated by comparing expressed genes between cells that support and do not support the proliferation or survival of these critical cells. This innovation has the potential to enhance the understanding and treatment of various blood-related disorders.

Career Highlights

Throughout his career, Ivan has worked with prominent companies such as Kirin Beer Kabushiki Kaisha and Nuvelo, Inc. His experience in these organizations has allowed him to apply his research in practical settings, contributing to advancements in biotechnology and medicine.

Collaborations

Ivan has collaborated with esteemed colleagues, including Radoje Drmanac and Y Tom Tang. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Ivan Lobal's contributions to the field of biotechnology, particularly through his patent and collaborations, highlight his role as an influential inventor. His work continues to pave the way for advancements in medical science and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…